Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Acta Diabetologica
Published in: Acta Diabetologica 5/2016

01-10-2016 | Original Article

Differential expression of microRNAs in plasma of patients with prediabetes and newly diagnosed type 2 diabetes

Authors: Shaoying Yan, Tianqiong Wang, Shengwen Huang, Yanan Di, Yunzhu Huang, Xingmei Liu, Zhenyuan Luo, Wenping Han, Bangquan An

Published in: Acta Diabetologica | Issue 5/2016

Login to get access

Abstract

Aims

MicroRNAs (miRNAs) are present in plasma and have emerged as critical regulators of gene expression at posttranscriptional level, and thus are involved in various human diseases, including diabetes. The objective of this study was to screen and validate differentially expressed plasma miRNAs in prediabetes and newly diagnosed type 2 diabetes (T2D).

Methods

In this study, we screened differentially expressed plasma miRNAs in prediabetes and newly diagnosed T2D by miRNA microarray analysis, and validated the expression of candidate miRNAs using quantitative reverse transcription polymerase chain reaction assays. Furthermore, we performed gene ontology (GO) and Kyoto encyclopedia of genes and genomes (KEGG) pathway analyses to disclose functional enrichment of genes predicted to be regulated by the differentially expressed miRNAs.

Results

Notably, our results revealed that hsa-miR-1249, hsa-miR-320b, and hsa-miR-572 (P < 0.05) were differentially expressed among the three groups, which yielded an area under the receiver operator characteristics curve (AUC) of 0.784 [95 % confidence interval (CI) 0.685–0.883], 0.946 (95 % CI 0.906–0.985), and 0.843 (95 % CI 0.766–0.920) discriminating T2D patients from NGT control groups, respectively, while the AUC was 0.887 (95 % CI 0.818–0.957), 0.635 (95 % CI 0.525–0.744), and 0.69 (95 % CI 0.580–0.793) discriminating prediabetes patients from NGT control groups, respectively. In addition, GO and KEGG pathway analyses showed that genes predicted to be regulated by differentially expressed miRNAs were significantly enriched in several related biological processes and pathways, including the development of multicellular organisms, signal transduction, cell differentiation, apoptosis, cell metabolism, ion transport regulation, and other biological functions.

Conclusions

Taken together, our results showed differentially expressed miRNAs in T2D and prediabetes. Plasma hsa-miR-1249, hsa-miR-320b, and hsa-miR-572 may serve as novel biomarkers for diagnosis and potential targets for the treatment for prediabetes and T2D.
Literature
1.
ADA (American Diabetes Association) (2013) Diagnosis and classification of diabetes mellitus. Diabetes Care 36(Suppl 1):S67–S74CrossRef
2.
ADA (American Diabetes Association) (2013) Standards of medical care in diabetes—2013. Diabetes Care 36(Suppl 1):S11–S66CrossRef
3.
Afghahi H, Miftaraj M, Svensson AM et al (2013) Ongoing treatment with renin-angiotensin-aldosterone-blocking agents does not predict normoalbuminuric renal impairment in a general type 2 diabetes population. J Diabetes Complicat 27:229–234CrossRefPubMed
4.
5.
Bentwich I, Avniel A, Karov Y et al (2005) Identification of hundreds of conserved and nonconserved human microRNAs. Nat Genet 37:766–770CrossRefPubMed
6.
Berezikov E, Guryev V, van de Belt J, Wienholds E, Plasterk RH, Cuppen E (2005) Phylogenetic shadowing and computational identification of human microRNA genes. Cell 120:21–24CrossRefPubMed
7.
Chen X, Ba Y, Ma L et al (2008) Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 18:997–1006CrossRefPubMed
8.
Curaba J, Singh MB, Bhalla PL (2014) miRNAs in the crosstalk between phytohormone signalling pathways. J Exp Bot 65:1425–1438CrossRefPubMed
9.
Daimiel-Ruiz L, Klett-Mingo M, Konstantinidou V et al (2015) Dietary lipids modulate the expression of miR-107, an miRNA that regulates the circadian system. Mol Nutr Food Res 59:552–565CrossRefPubMedPubMedCentral
10.
El OA, Baroukh N, Martens GA, Lebrun P, Pipeleers D, van Obberghen E (2008) miR-375 targets 3’-phosphoinositide-dependent protein kinase-1 and regulates glucose-induced biological responses in pancreatic beta-cells. Diabetes 57:2708–2717CrossRef
11.
Guariguata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U, Shaw JE (2014) Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract 103:137–149CrossRefPubMed
12.
Guay C, Regazzi R (2015) Role of islet microRNAs in diabetes: which model for which question? Diabetologia 58:456–463CrossRefPubMed
13.
Haug BH, Henriksen JR, Buechner J et al (2011) MYCN-regulated miRNA-92 inhibits secretion of the tumor suppressor DICKKOPF-3 (DKK3) in neuroblastoma. Carcinogenesis 32:1005–1012CrossRefPubMed
14.
He C (2013) The establishment of fingerprint spectrum of circulating microRNAs in early stage diabetic nephropathy. Chongqing Medical University, Chongqing, pp 1–53
15.
Igoillo-Esteve M, Marselli L, Cunha DA et al (2010) Palmitate induces a pro-inflammatory response in human pancreatic islets that mimics CCL2 expression by beta cells in type 2 diabetes. Diabetologia 53:1395–1405CrossRefPubMed
16.
Jacobs ME, Jeffers LA, Welch AK, Wingo CS, Cain BD (2013) The effect of aldosterone on the miRNA content of a murine inner medullary collecting duct cell. FASEB J 27:778
17.
Kong L, Zhu J, Han W et al (2011) Significance of serum microRNAs in pre-diabetes and newly diagnosed type 2 diabetes: a clinical study. Acta Diabetol 48:61–69CrossRefPubMed
18.
Kong L, Zhu J, Han W et al (2014) Serum miR-23a, a potential biomarker for diagnosis of pre-diabetes and type 2 diabetes. Acta Diabetol 51:823–831CrossRef
19.
Lewis BP, Burge CB, Bartel DP (2005) Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120:15–20CrossRefPubMed
20.
21.
Li Y, Jiang Z, Xu L, Yao H, Guo J, Ding X (2011) Stability analysis of liver cancer-related microRNAs. Acta Biochim Biophys Sin (Shanghai) 43:69–78CrossRef
22.
Liu AM, Wang W, Luk JM (2014) miRNAs: new tools for molecular classification, diagnosis and prognosis of hepatocellular carcinoma. Hepatic Oncol 1:323–329CrossRef
23.
Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25:402–408CrossRefPubMed
24.
Luo M, Li R, Deng X et al (2015) Platelet-derived miR-103b as a novel biomarker for the early diagnosis of type 2 diabetes. Acta Diabetol 52:943–949CrossRefPubMed
25.
Maharaj PD, Widen SG, Huang J, Wood TG, Thangamani S (2015) Discovery of mosquito saliva microRNAs during CHIKV infection. PLoS Negl Trop Dis 9:e3386CrossRef
26.
Nilsen TW (2007) Mechanisms of microRNA-mediated gene regulation in animal cells. Trends Genet 23:243–249CrossRefPubMed
27.
Papadopoulos T, Belliere J, Bascands JL, Neau E, Klein J, Schanstra JP (2015) miRNAs in urine: a mirror image of kidney disease? Expert Rev Mol Diagn 15:361–374CrossRefPubMed
28.
Raciti GA, Longo M, Parrillo L et al (2015) Understanding type 2 diabetes: from genetics to epigenetics. Acta Diabetol 52:821–827CrossRefPubMed
29.
Redova M, Sana J, Slaby O (2013) Circulating miRNAs as new blood-based biomarkers for solid cancers. Future Oncol 9:387–402CrossRefPubMed
30.
Salunkhe VA, Esguerra JL, Ofori JK et al (2015) Modulation of microRNA-375 expression alters voltage-gated Na(+) channel properties and exocytosis in insulin-secreting cells. Acta Physiol (Oxford) 213:882–892CrossRef
31.
Sebastiani G, Po A, Miele E et al (2015) MicroRNA-124a is hyperexpressed in type 2 diabetic human pancreatic islets and negatively regulates insulin secretion. Acta Diabetol 52:523–530CrossRefPubMed
32.
Shi P (2013) Analysis of the expression of circulating microRNA spectral in diabetic nephropathy patients. China Medical University, Shenyang, pp 1–38
33.
Tang X, Muniappan L, Tang G, Ozcan S (2009) Identification of glucose-regulated miRNAs from pancreatic beta cells reveals a role for miR-30d in insulin transcription. RNA 15:287–293CrossRefPubMedPubMedCentral
34.
Tang Y, Banan A, Forsyth CB et al (2008) Effect of alcohol on miR-212 expression in intestinal epithelial cells and its potential role in alcoholic liver disease. Alcohol Clin Exp Res 32:355–364CrossRefPubMed
35.
Tay HL, Plank M, Collison A, Mattes J, Kumar RK, Foster PS (2014) MicroRNA: potential biomarkers and therapeutic targets for allergic asthma? Ann Med 46:633–639CrossRefPubMed
36.
Whiting DR, Guariguata L, Weil C, Shaw J (2011) IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 94:311–321CrossRefPubMed
37.
Xie X, Lu J, Kulbokas EJ et al (2005) Systematic discovery of regulatory motifs in human promoters and 3’ UTRs by comparison of several mammals. Nature 434:338–345CrossRefPubMedPubMedCentral
38.
Yang W, Lu J, Weng J et al (2010) Prevalence of diabetes among men and women in China. N Engl J Med 362:1090–1101CrossRefPubMed
39.
Zampetaki A, Kiechl S, Drozdov I et al (2010) Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes. Circ Res 107:810–817CrossRefPubMed
40.
Zhang GJ (2011) Silicon nanowire biosensor for ultrasensitive and label-free direct detection of miRNAs. Methods Mol Biol 676:111–121CrossRefPubMed
Metadata
Title
Differential expression of microRNAs in plasma of patients with prediabetes and newly diagnosed type 2 diabetes
Authors
Shaoying Yan
Tianqiong Wang
Shengwen Huang
Yanan Di
Yunzhu Huang
Xingmei Liu
Zhenyuan Luo
Wenping Han
Bangquan An
Publication date
01-10-2016
Publisher
Springer Milan
Published in
Acta Diabetologica / Issue 5/2016
Print ISSN: 0940-5429
Electronic ISSN: 1432-5233
DOI
https://doi.org/10.1007/s00592-016-0837-1

Other articles of this Issue 5/2016

Acta Diabetologica 5/2016 Go to the issue

Original Article

Enhanced external counterpulsation (EECP) improves biomarkers of glycemic control in patients with non-insulin-dependent type II diabetes mellitus for up to 3 months following treatment

Original Article

Enhanced external counterpulsation (EECP) decreases advanced glycation end products and proinflammatory cytokines in patients with non-insulin-dependent type II diabetes mellitus for up to 6 months following treatment

Original Article

Prevalence and risk factors for prolonged QT interval and QT dispersion in patients with type 2 diabetes

Original Article

Incidence and correlated factors of beta cell failure in a 4-year follow-up of patients with type 2 diabetes: a longitudinal analysis of the BETADECLINE study

Original Article

History of mild hypoglycaemia does not affect the prevalence of diabetes-related distress in people with diabetes

Original Article

Impact of cancer diagnosis and treatment on glycaemic control among individuals with colorectal cancer using glucose-lowering drugs
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits